SCHEMBL22409469

SCHEMBL22409469

CCOP(=O)(CCN1CCN(CCC(CSc2ccccc2)NC(=O)O)CC1)OCC

nearest known ligand 0.39

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
HTR4 Q13639 1/20 0.39
ALDH1A1 P00352 6/20 0.39
KDM4E B2RXH2 2/20 0.39
HPGD P15428 1/20 0.37
BCL2L1 Q07817 2/20 0.37
NPC1 O15118 4/20 0.37
RAB9A P51151 4/20 0.37
HSD17B10 Q99714 1/20 0.36
MTNR1A P48039 3/20 0.36
MTNR1B P49286 3/20 0.36
SMN1; SMN2 Q16637 2/20 0.36
MAPT P10636 2/20 0.36
KCNA3 P22001 1/20 0.35
KMT2A Q03164 1/20 0.35
GLA P06280 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22409468 1.00 HTR4 (0.39) HTR4ALDH1A1KDM4EHPGDBCL2L1
SCHEMBL22409444 0.92 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDBCL2L1NPC1
SCHEMBL22409442 0.92 ALDH1A1 (0.39) ALDH1A1KDM4EHPGDBCL2L1NPC1
SCHEMBL19014884 0.89 BCL2L1 (0.38) HTR4ALDH1A1KDM4EBCL2L1
SCHEMBL22409437 0.84 BCL2L1 (0.38) ALDH1A1KDM4EHPGDBCL2L1NPC1
SCHEMBL22409436 0.84 BCL2L1 (0.38) ALDH1A1KDM4EHPGDBCL2L1NPC1
SCHEMBL22409429 0.84 SIGMAR1 (0.39) ALDH1A1KDM4EBCL2L1
SCHEMBL22409431 0.84 SIGMAR1 (0.39) ALDH1A1KDM4EBCL2L1
SCHEMBL22428656 0.82 NPC1 (0.40) HTR4ALDH1A1KDM4ENPC1RAB9A
SCHEMBL22409403 0.82 MTNR1A (0.39) ALDH1A1KDM4EBCL2L1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders UNITY BIOTECHNOLOGY, INC. (US) 2021-09-07 US disclosed
US-20200291050-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS UNITY BIOTECHNOLOGY, INC. 2020-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11111259-B2 Acylsulfonamide derivatives for treating senescence-associated diseases and disorders ACAT1, ARSA, GLA HTR4 4613/4885ALDH1A1 611/4885KDM4E 1998/4885
US-20200291050-A1 ACYLSULFONAMIDE DERIVATIVES FOR TREATING SENESCENCE-ASSOCIATED DISEASES AND DISORDERS ACAT1, ARSA, GLA HTR4 4613/4885ALDH1A1 611/4885KDM4E 1998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.